Resource Logo
AIDS Treatment Data Network

(ATDN) Another Option for under 50 T4 Cells




 

Treatment Review; August 1995

Crixivan is also being studied in a clinical trial. Like the expanded access program, less than 50 T4 cells are required to participate in this program. The trial will study 3 different drugs in combination and alone for the treatment of HIV infection. The drugs are Crixivan (MK-639), AZT and 3TC. You must have taken and tolerated AZT for more than 6 months at the standard dose to be eligible to participate. Participants will be divided into three groups. The first group will take AZT and 3TC. The second group will take the protease inhibitor. The third group will take all three study drugs together.

There is also a special, open label arm of this study for people who can't take AZT, have used AZT for less than six months, or have taken 3TC before.



 


Copyright © 1995 -AIDS Treatment Data Network, Publisher. All rights reserved to AIDS Treatment Data Network. Reproduction of this article (other than one copy for personal reference) must be cleared through the AIDS Treatment Data Network. Email AIDS Treatment Data Network

Information in this article was accurate in August 1, 1995. The state of the art may have changed since the publication date. This material is designed to support, not replace, the relationship that exists between you and your doctor. Always discuss treatment options with a doctor who specializes in treating HIV.